DataSheet1_Green extraction of puromycin-based antibiotics from Streptomyces albofaciens (MS38) for sustainable biopharmaceutical applications.docx

Background: Microbial secondary metabolites have shown promise as a source of novel antimicrobial agents. In this study, we aimed to isolate, characterize, and evaluate the antimicrobial activity of compound from a novel Streptomyces albofaciens strain MS38. The objective was to identify a potential bioactive compound with broad-spectrum antimicrobial properties.Methods: The isolated strain MS38 on starch casein agar was characterized using morphological, physiological, and molecular identification techniques. The compound was obtained from the fermented broth through extraction with n-butanol and further purification using silica gel column chromatography and high-performance liquid chromatography (HPLC). Structural elucidation was conducted using Ultraviolet (UV), Infrared (IR), nuclear magnetic resonance (NMR), and mass spectrometry (MS) techniques. The antimicrobial activity was evaluated using the agar well diffusion method and the microplate Alamar blue assay (MABA).Results: The isolated strain MS38 was identified as novel S. albofaciens based on morphological characteristics and confirmed by 16S sequences analysis and MALDI-TOF MS. The compound obtained from the fermented broth exhibited substantial antimicrobial activity against a variety of pathogenic bacteria and fungi. Structural analysis revealed a complex chemical structure with characteristic functional groups indicative of potential antimicrobial properties. The compound demonstrated strong activity against both Gram-positive (Staphylococcus Spp.) and Gram-negative (Klebsiella pneumoniae and Escherichia coli) bacteria, as well as fungi, including Candida albicans and Trichophyton rubrum.Conclusion: This study successfully isolated and characterized a bioactive compound from a novel S. albofaciens MS38. The compound exhibited significant antimicrobial activity against a range of pathogenic microorganisms. These findings underscore the importance of exploring microbial biodiversity for the discovery of novel antimicrobial agents. This study contributes to the growing knowledge of microbial secondary metabolites with potential therapeutic value.

背景：微生物次级代谢产物在新型抗菌剂的来源中展现出巨大的潜力。在本研究中，我们的目标是分离、鉴定和评估一种新型链霉菌属（Streptomyces）白菌（albofaciens）菌株MS38中化合物的抗菌活性。目的在于鉴定一种具有广谱抗菌特性的潜在生物活性化合物。方法：采用形态学、生理学及分子鉴定技术对淀粉酪蛋白琼脂上的分离菌株MS38进行鉴定。化合物通过从发酵液中用正丁醇提取，并使用硅胶柱层析和高效液相色谱（HPLC）进行进一步纯化而获得。结构阐明采用紫外（UV）、红外（IR）、核磁共振（NMR）和质谱（MS）技术进行。抗菌活性通过琼脂孔扩散法和微孔板Alamar蓝试验（MABA）进行评估。结果：分离的菌株MS38根据形态学特征被鉴定为新型S. albofaciens，并通过16S序列分析和基质辅助激光解吸电离飞行时间质谱（MALDI-TOF MS）得到证实。从发酵液中获得的化合物对多种致病细菌和真菌表现出显著的抗菌活性。结构分析揭示了具有潜在抗菌特性的特征官能团的复杂化学结构。该化合物对革兰氏阳性菌（如葡萄球菌属Staphylococcus Spp.）、革兰氏阴性菌（如肺炎克雷伯菌Klebsiella pneumoniae和大肠杆菌Escherichia coli）以及真菌（包括白色念珠菌Candida albicans和红色毛癣菌Trichophyton rubrum）均表现出强效活性。结论：本研究成功从新型链霉菌属白菌MS38中分离并鉴定了一种生物活性化合物。该化合物对多种致病微生物表现出显著的抗菌活性。这些发现强调了探索微生物多样性以发现新型抗菌剂的重要性。本研究为具有潜在治疗价值的微生物次级代谢物的知识积累做出了贡献。